Detalhe da pesquisa
1.
Population pharmacokinetic and exposure-efficacy analysis of ixekizumab in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS).
Br J Clin Pharmacol
; 88(3): 1074-1086, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34378230
2.
A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer.
Invest New Drugs
; 38(4): 1145-1155, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31707688
3.
A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer.
Gynecol Oncol
; 156(1): 23-31, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31791552
4.
Systematic Modeling and Design Evaluation of Unperturbed Tumor Dynamics in Xenografts.
J Pharmacol Exp Ther
; 366(1): 96-104, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29691287
5.
Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer.
Invest New Drugs
; 36(4): 629-637, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29196957
6.
Characterizing Gemcitabine Effects Administered as Single Agent or Combined with Carboplatin in Mice Pancreatic and Ovarian Cancer Xenografts: A Semimechanistic Pharmacokinetic/Pharmacodynamics Tumor Growth-Response Model.
J Pharmacol Exp Ther
; 360(3): 445-456, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28028124
7.
Ixekizumab Citrate-Free Formulation: Results from Two Clinical Trials.
Adv Ther
; 39(6): 2862-2872, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35449322
8.
Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination with Durvalumab in Advanced Refractory Solid Tumors.
J Pancreat Cancer
; 6(1): 21-31, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32219196
9.
Translational Framework Predicting Tumour Response in Gemcitabine-Treated Patients with Advanced Pancreatic and Ovarian Cancer from Xenograft Studies.
AAPS J
; 21(2): 23, 2019 01 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-30706160
10.
Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice.
Eur J Cancer
; 44(1): 142-50, 2008 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-18039567
11.
Predicting tumour growth and its impact on survival in gemcitabine-treated patients with advanced pancreatic cancer.
Eur J Pharm Sci
; 115: 296-303, 2018 Mar 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-29366960
12.
Phase I Study of LY2940680, a Smo Antagonist, in Patients with Advanced Cancer Including Treatment-Naïve and Previously Treated Basal Cell Carcinoma.
Clin Cancer Res
; 24(9): 2082-2091, 2018 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29483143
13.
A phase 1 study of the Janus kinase 2 (JAK2)V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia.
Leuk Res
; 61: 89-95, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28934680
14.
A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer.
Clin Cancer Res
; 22(5): 1095-102, 2016 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26581242
15.
A phase I dose-escalation study to a predefined dose of a transforming growth factor-ß1 monoclonal antibody (TßM1) in patients with metastatic cancer.
Int J Oncol
; 45(6): 2221-31, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25270361